ARMGO Pharma Enrolls First Affected person in Part 2 Trial of ARM210 for the Therapy of Catecholaminergic Polymorphic Ventricular Tachycardia
ARMGO Pharma, Inc. (ARMGO), a scientific stage biopharmaceutical firm advancing a novel class of small [...]
